OncoSec Medical Incorporated (ONCSQ)
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Mit einem Kurs von $ ist OncoSec Medical Incorporated (ONCSQ) ein Healthcare-Unternehmen mit einer Bewertung von 0. Die Aktie erzielt 52/100, eine moderate Bewertung basierend auf 9 quantitativen KPIs.
Zuletzt analysiert: 16. März 2026OncoSec Medical Incorporated (ONCSQ) Gesundheitswesen & Pipeline-Uebersicht
OncoSec Medical Incorporated, an immuno-oncology company, focused on intra-tumoral DNA-based therapeutics to stimulate anti-tumor immune responses. Despite clinical trial collaborations with Merck and Duke University, the company filed for Chapter 7 liquidation in 2023, impacting its pipeline of cancer treatments and COVID-19 therapies. The company's stock trades on the OTC market.
Investmentthese
OncoSec Medical Incorporated's Chapter 7 liquidation filing in June 2023 represents a significant event for investors. The company's pipeline, which included multiple Phase 1 and Phase 2 clinical trials, is now subject to the bankruptcy proceedings. Key collaborations with Merck and Duke University are unlikely to continue. The company's market capitalization was $0.00B prior to liquidation. The high beta of 9.96 indicates extreme volatility, which is now largely irrelevant given the bankruptcy. Investors should be aware that recovery on OTC stocks after bankruptcy is highly uncertain.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- OncoSec Medical Incorporated filed for Chapter 7 liquidation on June 14, 2023.
- The company's market capitalization was $0.00B prior to liquidation.
- The company's pipeline included multiple Phase 1 and Phase 2 clinical trials targeting various cancers and COVID-19.
- OncoSec had clinical trial collaborations with Merck & Co., Inc. and research collaboration with Duke University.
- The stock trades on the OTC market, specifically the OTC Other tier.
Wettbewerber & Vergleichsunternehmen
Staerken
- Proprietary DNA-based therapeutic technology.
- Clinical trial collaborations with established institutions.
- Diverse pipeline of immuno-oncology treatments.
Schwaechen
- Chapter 7 liquidation filing.
- Dependence on collaborations for funding.
- High risk of clinical trial failure.
Katalysatoren
- N/A: OncoSec Medical Incorporated filed for Chapter 7 liquidation on June 14, 2023.
Risiken
- Ongoing: Chapter 7 bankruptcy proceedings.
- Ongoing: Loss of intellectual property.
- Ongoing: Inability to continue clinical trials.
- Potential: Legal claims from creditors.
- Potential: Delisting from the OTC market.
Wachstumschancen
- N/A: OncoSec Medical Incorporated filed for Chapter 7 liquidation on June 14, 2023. Therefore, there are no growth opportunities.
- N/A: OncoSec Medical Incorporated filed for Chapter 7 liquidation on June 14, 2023. Therefore, there are no growth opportunities.
- N/A: OncoSec Medical Incorporated filed for Chapter 7 liquidation on June 14, 2023. Therefore, there are no growth opportunities.
- N/A: OncoSec Medical Incorporated filed for Chapter 7 liquidation on June 14, 2023. Therefore, there are no growth opportunities.
- N/A: OncoSec Medical Incorporated filed for Chapter 7 liquidation on June 14, 2023. Therefore, there are no growth opportunities.
Chancen
- N/A due to liquidation filing.
Risiken
- Bankruptcy proceedings.
- Loss of intellectual property.
- Inability to continue clinical trials.
Wettbewerbsvorteile
- Proprietary intra-tumoral DNA-based therapeutic technology.
- Clinical trial collaborations with Merck & Co., Inc. and Duke University.
- Pipeline of Phase 1 and Phase 2 clinical trials.
Ueber ONCSQ
OncoSec Medical Incorporated, formerly known as NetVentory Solutions Inc., was founded in 2008 and rebranded in March 2011 to focus on immuno-oncology. Headquartered in Pennington, New Jersey, the company specialized in designing, developing, and commercializing intra-tumoral DNA-based therapeutics aimed at stimulating and augmenting anti-tumor immune responses for cancer treatment. Their product pipeline included KEYNOTE-695, a Phase 2 trial for advanced melanoma, and TAVO + SARS-CoV-2 spike glycoprotein, a Phase 1 clinical trial for COVID-19. Additional trials included TAVO + epacadostat + pembrolizumab for squamous cell carcinoma of the head and neck, TAVO + nivolumab for breast cancer, and TAVO + CXCL9 for solid tumors, along with OMS-100 and OMS-102 for metastatic melanoma. OncoSec collaborated with Merck & Co., Inc. on KEYNOTE-695 and KEYNOTE-890 and with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination with a HER2-plasmid vaccine. However, on June 14, 2023, OncoSec filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of New Jersey, ceasing its operations and development programs.
Was das Unternehmen tut
- Developed intra-tumoral DNA-based therapeutics.
- Focused on stimulating anti-tumor immune responses.
- Conducted Phase 1 and Phase 2 clinical trials for cancer treatments.
- Developed a COVID-19 therapy in Phase 1 clinical trial.
- Collaborated with Merck & Co., Inc. on clinical trials.
- Partnered with Duke University for research.
Geschaeftsmodell
- Focused on developing and commercializing immuno-oncology therapeutics.
- Generated revenue through potential future sales of approved therapies.
- Relied on collaborations and partnerships for funding and clinical trials.
Branchenkontext
OncoSec Medical Incorporated operated within the competitive biotechnology industry, focusing on immuno-oncology. This sector involves developing therapies that harness the body's immune system to fight cancer. The industry is characterized by high research and development costs, lengthy clinical trial processes, and regulatory hurdles. Companies like OncoSec often collaborate with larger pharmaceutical firms to fund and conduct clinical trials. The failure rate for biotechnology companies is high, and OncoSec's bankruptcy reflects the challenges inherent in bringing novel therapies to market. Competitors focus on similar immuno-oncology approaches, creating a crowded and dynamic landscape.
Wichtige Kunden
- Patients with advanced melanoma.
- Patients with squamous cell carcinoma of the head and neck.
- Patients with breast cancer.
- Patients with solid tumors.
- Patients with COVID-19.
Finanzdaten
Chart & Info
OncoSec Medical Incorporated (ONCSQ) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Keine aktuellen Nachrichten fuer ONCSQ verfuegbar.
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer ONCSQ.
Kursziele
Wall-Street-Kurszielanalyse fuer ONCSQ.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von ONCSQ auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
ONCSQ OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, encompassing stocks that may not meet the minimum financial standards or have chosen not to provide current information to the market. These securities often include companies in bankruptcy, those with regulatory issues, or those that are thinly traded. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and limited financial disclosure compared to exchanges like the NYSE or NASDAQ.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure.
- Low liquidity and wide bid-ask spreads.
- Potential for fraud or manipulation.
- Bankruptcy risk.
- Lack of regulatory oversight.
- Verify the company's bankruptcy status with the U.S. Bankruptcy Court.
- Attempt to locate any available financial statements.
- Assess the trading volume and bid-ask spread.
- Consult with a financial advisor.
- Understand the risks associated with OTC Other stocks.
- Determine the potential for recovery in bankruptcy proceedings.
- Research the company's assets and liabilities.
- Prior clinical trial collaborations with Merck & Co., Inc. and Duke University.
- Previous focus on developing immuno-oncology therapies.
- Listing on the OTC market, despite the bankruptcy.
Haeufige Fragen zu ONCSQ
What are the key factors to evaluate for ONCSQ?
OncoSec Medical Incorporated (ONCSQ) currently holds an AI score of 52/100, indicating moderate score. Key strength: Proprietary DNA-based therapeutic technology.. Primary risk to monitor: Ongoing: Chapter 7 bankruptcy proceedings.. This is not financial advice.
How frequently does ONCSQ data refresh on this page?
ONCSQ prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ONCSQ's recent stock price performance?
Recent price movement in OncoSec Medical Incorporated (ONCSQ) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary DNA-based therapeutic technology.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ONCSQ overvalued or undervalued right now?
Determining whether OncoSec Medical Incorporated (ONCSQ) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ONCSQ?
Before investing in OncoSec Medical Incorporated (ONCSQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding ONCSQ to a portfolio?
Potential reasons to consider OncoSec Medical Incorporated (ONCSQ) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Proprietary DNA-based therapeutic technology.. Additionally: Clinical trial collaborations with established institutions.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of ONCSQ?
Yes, most major brokerages offer fractional shares of OncoSec Medical Incorporated (ONCSQ) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track ONCSQ's earnings and financial reports?
OncoSec Medical Incorporated (ONCSQ) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for ONCSQ earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Information is based on publicly available sources and may be subject to change due to the ongoing bankruptcy proceedings.